Cargando…

Brief Report: Selection of HIV-1 Variants With Higher Transmission Potential by 1% Tenofovir Gel Microbicide

BACKGROUND: Women in the CAPRISA 004 trial assigned to use 1% tenofovir (TFV) microbicide gel, who became HIV-1 infected, had higher viral load set-point and slower antibody avidity maturation compared with placebo participants. We investigated whether TFV gel was selected for viruses with altered g...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ngandu, Nobubelo K., Carlson, Jonathan M., Chopera, Denis R., Ndabambi, Nonkululeko, Abdool Karim, Quarraisha, Abdool Karim, Salim, Williamson, Carolyn
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	JAIDS Journal of Acquired Immune Deficiency Syndromes 2017
Materias:	Prevention Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5576519/ https://www.ncbi.nlm.nih.gov/pubmed/28797020 http://dx.doi.org/10.1097/QAI.0000000000001458

Ejemplares similares

No Evidence for Selection of HIV-1 with Enhanced Gag-Protease or Nef Function among Breakthrough Infections in the CAPRISA 004 Tenofovir Microbicide Trial
por: Chopera, Denis R., et al.
Publicado: (2013)

Trial participation disclosure and gel use behavior in the CAPRISA 004 tenofovir gel trial
por: Succop, Stacey M., et al.
Publicado: (2014)

Infrequent, low magnitude HIV-specific T cell responses in HIV-uninfected participants in the 1% tenofovir microbicide gel trial (CAPRISA004)
por: Burgers, WA, et al.
Publicado: (2012)

Microbicides & their implications in HIV prevention
por: Karim, Salim S. Abdool, et al.
Publicado: (2010)

Assessing Adherence in the CAPRISA 004 Tenofovir Gel HIV Prevention Trial: Results of a Nested Case–Control Study
por: MacQueen, Kathleen M., et al.
Publicado: (2014)

Social Context of Adherence in an Open-Label 1 % Tenofovir Gel Trial: Gender Dynamics and Disclosure in KwaZulu-Natal, South Africa
por: MacQueen, Kathleen M., et al.
Publicado: (2016)

Omicron SARS-CoV-2 variant: a new chapter in the COVID-19 pandemic
por: Karim, Salim S Abdool, et al.
Publicado: (2021)

Genital inflammation undermines the effectiveness of tenofovir gel in preventing HIV acquisition in women
por: McKinnon, Lyle R., et al.
Publicado: (2018)

Identifying SARS-CoV-2 infections in South Africa: Balancing public health imperatives with saving lives
por: Baxter, Cheryl, et al.
Publicado: (2021)

Women with Pregnancies Had Lower Adherence to 1% Tenofovir Vaginal Gel as HIV Preexposure Prophylaxis in CAPRISA 004, a Phase IIB Randomized-Controlled Trial
por: Matthews, Lynn T., et al.
Publicado: (2013)

Assessing the implementation effectiveness and safety of 1% tenofovir gel provision through family planning services in KwaZulu-Natal, South Africa: study protocol for an open-label randomized controlled trial
por: Mansoor, Leila E, et al.
Publicado: (2014)

ARV-based HIV prevention for women – where we are in 2014
por: Mastro, Timothy D, et al.
Publicado: (2014)

Recruitment of high risk women for HIV prevention trials: baseline HIV prevalence and sexual behavior in the CAPRISA 004 tenofovir gel trial
por: Karim, Quarraisha Abdool, et al.
Publicado: (2011)

Enrolling Adolescents in Research on HIV and Other Sensitive Issues: Lessons from South Africa
por: Singh, Jerome Amir, et al.
Publicado: (2006)

Vaginal deployment and tenofovir delivery by microbicide gels
por: Gao, Y., et al.
Publicado: (2015)

Frequency of Hepatitis B Virus Resistance Mutations in Women Using Tenofovir Gel as Pre-Exposure Prophylaxis
por: Baxter, Cheryl, et al.
Publicado: (2019)

Changes in Natural Killer Cell Activation and Function during Primary HIV-1 Infection
por: Naranbhai, Vivek, et al.
Publicado: (2013)

Clinical Trials of Broadly Neutralizing Monoclonal Antibodies for Human Immunodeficiency Virus Prevention: A Review
por: Mahomed, Sharana, et al.
Publicado: (2020)

Topical Tenofovir Pre-exposure Prophylaxis and Mucosal HIV-Specific Fc-Mediated Antibody Activities in Women
por: Fisher, Kimone Leigh, et al.
Publicado: (2020)

Current status of the HIV epidemic & challenges in prevention
por: Karim, Quarraisha Abdool
Publicado: (2017)

Mechanisms of sexually transmitted infection‐induced inflammation in women: implications for HIV risk
por: Mwatelah, Ruth, et al.
Publicado: (2019)

Distinct genital tract HIV-specific antibody profiles associated with tenofovir gel
por: Archary, D, et al.
Publicado: (2016)

South African HIV-1 subtype C transmitted variants with a specific V2 motif show higher dependence on α4β7 for replication
por: Richardson, Simone I, et al.
Publicado: (2015)

Inclusion of adolescent girls in HIV prevention research – an imperative for an AIDS-free generation
por: Karim, Quarraisha Abdool, et al.
Publicado: (2014)

COVID-19: Impact on the HIV and Tuberculosis Response, Service Delivery, and Research in South Africa
por: Abdool Karim, Quarraisha, et al.
Publicado: (2022)

Beneficial HLA-mediated viral polymorphisms on the transmitted virus additively influence disease progression in HIV-1, subtype C infection
por: Ntale, RS, et al.
Publicado: (2012)

Establishing a Cohort at High Risk of HIV Infection in South Africa: Challenges and Experiences of the CAPRISA 002 Acute Infection Study
por: van Loggerenberg, Francois, et al.
Publicado: (2008)

Higher mucosal antibody concentrations in women with genital tract inflammation
por: Sobia, Parveen, et al.
Publicado: (2021)

Enhancing oral PrEP uptake among adolescent girls and young women in Africa
por: Heck, Craig J., et al.
Publicado: (2022)

Utility of colposcopy in a phase 2 portion of a microbicide clinical trial of BufferGel and 0.5% PRO 2000 Gel
por: Chirenje, Zvavahera M, et al.
Publicado: (2012)

CAPRISA 018: a phase I/II clinical trial study protocol to assess the safety, acceptability, tolerability and pharmacokinetics of a sustained-release tenofovir alafenamide subdermal implant for HIV prevention in women
por: Gengiah, Tanuja Narayansamy, et al.
Publicado: (2022)

HIV prevalence among high school learners - opportunities for schools-based HIV testing programmes and sexual reproductive health services
por: Kharsany, Ayesha BM, et al.
Publicado: (2012)

Honing in on enteric fever
por: McKinnon, Lyle R, et al.
Publicado: (2014)

Low adverse event rates following voluntary medical male circumcision in a high HIV disease burden public sector prevention programme in South Africa
por: Phili, Rogerio, et al.
Publicado: (2014)

Putting women in the centre of the global HIV response is key to achieving epidemic control!
por: Abdool Karim, Quarraisha, et al.
Publicado: (2020)

Ratio of Monocytes to Lymphocytes in Peripheral Blood Identifies Adults at Risk of Incident Tuberculosis Among HIV-Infected Adults Initiating Antiretroviral Therapy
por: Naranbhai, Vivek, et al.
Publicado: (2014)

Adolescent girls and young women: key populations for HIV epidemic control
por: Dellar, Rachael C, et al.
Publicado: (2015)

Identification of adolescent girls and young women for targeted HIV prevention: a new risk scoring tool in KwaZulu Natal, South Africa
por: Ayton, Sarah Gabrielle, et al.
Publicado: (2020)

Ex vivo HIV entry into blood CD4+ T cells does not predict heterosexual HIV acquisition in women
por: Joag, Vineet, et al.
Publicado: (2018)

High incidence and persistence of hepatitis B virus infection in individuals receiving HIV care in KwaZulu-Natal, South Africa
por: Msomi, Nokukhanya, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_7u9bfrvul3j9gtqm17348acbhs